文章摘要
朱妍妍,柏智能,唐丽琴.反相高效液相色谱法测定硫唑嘌呤代谢产物6-巯基嘌呤血浆药物浓度[J].安徽医药,2016,20(6):1081-1083.
反相高效液相色谱法测定硫唑嘌呤代谢产物6-巯基嘌呤血浆药物浓度
Determination of 6-mercaptopurine in human plasma by RP-HPLC
投稿时间:2016-04-06  
DOI:
中文关键词: 硫唑嘌呤  色谱法,反相  血药浓度
英文关键词: Azathioprine  Chromatography,reverse-phase  Plasma concentration
基金项目:
作者单位E-mail
朱妍妍 安徽中医药大学,安徽 合肥 230031
安徽省立医院,安徽 合肥 230001 
 
柏智能 安徽中医药大学,安徽 合肥 230031
安徽省立医院,安徽 合肥 230001 
 
唐丽琴 安徽省立医院,安徽 合肥 230001 tulcyl@vip.sina.com 
摘要点击次数: 2576
全文下载次数: 112
中文摘要:
      目的 建立反相高效液相色谱法(RP-HPLC)检测人血浆中硫唑嘌呤(AZA)代谢产物6-巯基嘌呤(6-MP)的浓度,为临床进行血药浓度监测提供基础。方法 采用Hypersil ODS2色谱柱(250 nm×4.6 nm,5 μm),流动相为乙腈-0.3%冰乙酸化(3∶97),流速为0.8 mL·min-1,检测波长323 nm,血浆样品经15%高氯酸去蛋白后加氢氧钠(NaOH)调节pH后20 μL进样分析。结果 6-MP血浆样品在0.02~2.00 mg·L-1范围内线性关系良好,最低检测下限(LLOQ)为0.02 mg·L-1;LLOQ、高浓度(1.5 mg·L-1)、中浓度(1 mg·L-1)和低浓度(0.05 mg·L-1)提取回收率分别为85.71%、92.93%、103.53%和96.02%,质控四个浓度的日内与日间精密度均<15.0%,符合中国药典生物样本分析相关规定。结论 该实验成功建立一种简单、快速、高灵敏度的6-MP血浆浓度测定方法,符合AZA血药浓度监测和药代动力学研究的相关规定。
英文摘要:
      Objective To establish a reversed phase high-performance liquid chromatography(RP-HPLC)method to determine 6-mercaptopurine (6-MP) in human plasma,thereby providing the foundation for clinical blood concentration monitoring.Methods Using Hypersil ODS2 column (250 nm ×4.6 nm,5 μm),the mobile phase was acetonitrile -0.3% glacial acetic acid (3∶97),the flow rate was 0.8 mL · min-1,the detection wavelength was set at 323 nm,and plasma samples were extracted by 20 μL 15% perchloric acid.Results A linearity was observed within the rangefrom 0.02 mg ·L-1to 2.00 mg ·L-1,the lowest detection limit was 0.02 mg ·L-1,the average method recovery rate of four concentrations were 85.71%,92.93%,103.53% and 96.02%,respectively,and the intra-day and inter-day precision are<15% and in line with the Chinese Pharmacopoeia biological sample analysis regulations.Conclusions The experiment successfully established a simple,fast,and low cost 6-MP plasma concentration measuring method with high sensitivity and good stability.Particularly,the method needs less blood.It is also in line with the relevant provisions of the AZA blood drug concentration monitoring and pharmacokinetics study.
查看全文   查看/发表评论  下载PDF阅读器
关闭

分享按钮